James M Isbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5891916/publications.pdf

Version: 2024-02-01

95 5,145 33
papers citations h-index

96 96 96 7841 all docs docs citations times ranked citing authors

69

g-index

#	Article	IF	CITATIONS
1	The American College of Surgeons Surgical Risk Calculator performs well for pulmonary resection: AÂvalidation study. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1509-1516.e1.	0.4	6
2	The emerging role of local therapy in oligometastatic non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 819-825.	0.4	7
3	A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. Annals of Surgery, 2022, 276, 312-317.	2.1	13
4	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 89-102.	0.5	16
5	Patterns and influence of nodal metastases after neoadjuvant chemoradiation and RO resection in esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 411-419.	0.4	4
6	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
7	Amiodarone with or without <i>N</i> -Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial. Anesthesiology, 2022, 136, 916-926.	1.3	10
8	Postinduction therapy pulmonary function retesting is necessary before surgical resection for non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 389-397.e7.	0.4	2
9	Two-Year Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy. Annals of Thoracic Surgery, 2021, 112, 880-889.	0.7	13
10	External Validation of Surgical Risk Preoperative Assessment System in Pulmonary Resection. Annals of Thoracic Surgery, 2021, 112, 228-237.	0.7	5
11	Pericardial Effusions in Patients With Cancer: Anesthetic Management and Survival Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 571-577.	0.6	1
12	Performance Comparison Between SURPAS and ACS NSQIP Surgical Risk Calculator in Pulmonary Resection. Annals of Thoracic Surgery, 2021, 111, 1643-1651.	0.7	7
13	How Effective Is Neoadjuvant Therapy Followed by Surgery for Pathologic Single-Station N2 Non–Small Cell Lung Cancer?. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 206-216.	0.4	6
14	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	3.2	20
15	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. British Journal of Anaesthesia, 2021, 127, 75-84.	1.5	33
16	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3656.	1.7	8
17	Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC. JTO Clinical and Research Reports, 2021, 2, 100209.	0.6	7
18	Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis. British Journal of Anaesthesia, 2021, 127, e82-e85.	1.5	5

#	Article	IF	CITATIONS
19	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
20	Treatment of anastomotic recurrence after esophagectomy. Annals of Thoracic Surgery, 2021, , .	0.7	4
21	Primary lung cancer in women after previous breast cancer. BJS Open, 2021, 5, .	0.7	6
22	Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	5
23	Goal-directed resuscitation following cardiac surgery reduces acute kidney injury: A quality initiative pre–post analysis. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1868-1877.e1.	0.4	24
24	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 1844-1856.	0.5	83
25	Is Routine Chest Radiography Necessary After Endobronchial Ultrasound–guided Fine Needle Aspiration?. Annals of Thoracic Surgery, 2020, 112, 467-472.	0.7	0
26	Time-varying analysis of readmission and mortality during the first year after pneumonectomy. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 247-255.e5.	0.4	11
27	Prognostic factors following complete resection of non-superior sulcus lung cancer invading the chest wall. European Journal of Cardio-thoracic Surgery, 2020, 58, 78-85.	0.6	10
28	COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: AÂConsensus Statement From Thoracic Surgery Outcomes Research Network. Annals of Thoracic Surgery, 2020, 110, 692-696.	0.7	72
29	COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 601-605.	0.4	52
30	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
31	Propensity-matched Analysis Demonstrates Long-term Risk of Respiratory and Cardiac Mortality After Pneumonectomy Compared With Lobectomy for Lung Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	4
32	Frequency and outcomes of brain metastases in patients with ⟨i⟩HER2⟨ i⟩â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	2.0	51
33	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	3.2	30
34	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology, 2019, 30, 597-603.	0.6	114
35	Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2469-2477.e10.	0.4	32
36	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 269-276.	0.4	218

#	Article	IF	Citations
37	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
38	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
39	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	3.0	96
40	Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients. Annals of Surgery, 2019, 270, 1161-1169.	2.1	27
41	Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2628-2631.	0.4	10
42	Preoperative anemia versus blood transfusion: Which is the culprit for worse outcomes in cardiac surgery?. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 66-74.e2.	0.4	97
43	Quality of Endoscopy Reports for Esophageal Cancer Patients: Where Do We Stand?. Journal of Gastrointestinal Surgery, 2018, 22, 778-784.	0.9	4
44	Predictors of Nodal Metastases for Clinical T2NO Esophageal Adenocarcinoma. Annals of Thoracic Surgery, 2018, 106, 172-177.	0.7	13
45	Factors associated with distant recurrence following RO lobectomy for pNO lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1212-1224.e3.	0.4	23
46	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Annals of Thoracic Surgery, 2018, 106, 178-183.	0.7	96
47	Implementing a Thoracic Enhanced Recovery Program: Lessons Learned in the First Year. Annals of Thoracic Surgery, 2018, 105, 1597-1604.	0.7	128
48	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2710-2721.e3.	0.4	41
49	Assessment of Fluorodeoxyglucose F18–Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules. JAMA Surgery, 2018, 153, 329.	2.2	26
50	Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Annals of Thoracic Surgery, 2018, 106, 864-871.	0.7	26
51	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of Oncology, 2018, 29, 1853-1860.	0.6	304
52	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell LungÂCancer. Annals of Thoracic Surgery, 2018, 106, 848-855.	0.7	17
53	Obesity Increases Riskâ€Adjusted Morbidity, Mortality, and Cost Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	91
54	Prospective study of giant paraesophageal hernia repair with 1-year follow-up. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 743-751.	0.4	18

#	Article	IF	Citations
55	Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced exÂvivo lung perfusion using adenosine A2B receptor antagonism. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1811-1820.	0.4	38
56	Defining quality in the surgical care of lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1397-1403.	0.4	15
57	Postoperative Hypoglycemia Is Associated With Worse Outcomes After Cardiac Operations. Annals of Thoracic Surgery, 2017, 103, 526-532.	0.7	22
58	Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non–Small-Cell Lung Cancer: A Competing Risks Analysis. Journal of Clinical Oncology, 2017, 35, 281-290.	0.8	170
59	Lung Cancer Screening in the Post–National Lung Screening Trial Era: Applying Screening in the Real World. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 526-530.	0.4	1
60	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology, 2017, 2017, 1-5.	0.6	20
61	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Annals of Translational Medicine, 2017, 5, 479-479.	0.7	11
62	Jejunal administration of glucose enhances acyl ghrelin suppression in obese humans. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E252-E259.	1.8	9
63	Enteral Access is not Required for Esophageal Cancer Patients Undergoing Neoadjuvant Therapy. Annals of Thoracic Surgery, 2016, 102, 948-954.	0.7	16
64	Preoperative Renal Function Predicts Hospital Costs and Length of Stay in Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2016, 101, 606-612.	0.7	18
65	Donation After Circulatory Death Lungs Transplantable Up to Six Hours After ExÂVivo Lung Perfusion. Annals of Thoracic Surgery, 2016, 102, 1845-1853.	0.7	28
66	Multiparameter Predictor of Fluid Responsiveness in Cardiac Surgical Patients Receiving Tidal Volumes Less Than 10 mL/kg. Seminars in Cardiothoracic and Vascular Anesthesia, 2016, 20, 188-196.	0.4	1
67	Extracorporeal life support for adult cardiopulmonary failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2015, 29, 229-239.	1.7	11
68	Risk Factors for Urinary Tract Infections in Cardiac Surgical Patients. Surgical Infections, 2015, 16, 504-508.	0.7	17
69	AKI Associated with Cardiac Surgery. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 500-514.	2.2	232
70	Population-specific models of glycemic control in intensive care: Towards a simulation-based methodology for protocol optimization., 2015, 2015, 5084-5090.		1
71	Bundled Payments in Cardiac Surgery: Is Risk Adjustment Sufficient to Make It Feasible?. Annals of Thoracic Surgery, 2015, 100, 1646-1652.	0.7	21
72	Multicenter Evaluation of High-Risk Mitral Valve Operations: Implications for Novel Transcatheter Valve Therapies. Annals of Thoracic Surgery, 2014, 98, 2032-2038.	0.7	4

#	Article	IF	CITATIONS
73	Impact of hemodynamic monitoring on clinical outcomes. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2014, 28, 463-476.	1.7	11
74	Planned Cardiac Reexploration in the Intensive Care Unit Is a Safe Procedure. Annals of Thoracic Surgery, 2014, 98, 1645-1652.	0.7	12
75	Mitral valve repair rates correlate with surgeon and institutional experience. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 995-1004.	0.4	71
76	Predictors of Early Recurrence for Node-Negative T1 to T2b Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2014, 98, 1175-1183.	0.7	39
77	Early Removal of Urinary Catheter After Surgery Requiring Thoracic Epidural: A Prospective Trial. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1302-1306.	0.6	32
78	Surgical Care Improvement Project measure for postoperative glucose control should not be used as a measure of quality after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1041-1048.	0.4	17
79	Marginal pulmonary function should not preclude lobectomy inÂselected patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 738-746.	0.4	38
80	Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2261-2267.e1.	0.4	95
81	Understanding Mortality as a Quality Indicator After Esophagectomy. Annals of Thoracic Surgery, 2014, 98, 506-512.	0.7	57
82	Postoperative Mortality Is an Inadequate Quality Indicator for Lung Cancer Resection. Annals of Thoracic Surgery, 2014, 97, 973-979.	0.7	59
83	Leiomyoma Presenting asÂa Massive Calcified Circumferential Esophageal Mass. Annals of Thoracic Surgery, 2013, 96, 1851-1854.	0.7	5
84	Effects of Proximal Gut Bypass on Glucose Tolerance and Insulin Sensitivity in Humans. Diabetes Care, 2013, 36, e57-e57.	4.3	16
85	Induction Chemoradiotherapy and Surgery forÂEsophageal Cancer: Survival Benefit WithÂDownstaging. Annals of Thoracic Surgery, 2013, 96, 225-231.	0.7	12
86	Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2011, 300, G795-G802.	1.6	73
87	Parenchymal-Sparing Lung Resections: Technique of Sleeve Resections. Operative Techniques in Thoracic and Cardiovascular Surgery, 2011, 16, 215-225.	0.2	0
88	Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation. Annals of Thoracic Surgery, 2011, 91, 227-233.	0.7	52
89	Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery, 2010, 147, 282-287.	1.0	56
90	The Importance of Caloric Restriction in the Early Improvements in Insulin Sensitivity After Roux-en-Y Gastric Bypass Surgery. Diabetes Care, 2010, 33, 1438-1442.	4.3	229

#	Article	IF	CITATIONS
91	Blunt posterior tracheal laceration and esophageal injury in a child. Journal of Pediatric Surgery, 2009, 44, 1292-1294.	0.8	11
92	Risk of Malignancy in Resected Cystic Tumors of the Pancreas ≧Âcm in Size: Is it Safe to Observe Asymptomatic Patients? A Multi-institutional Report. Journal of Gastrointestinal Surgery, 2008, 12, 234-242.	0.9	177
93	Damage Control Hematology: The Impact of a Trauma Exsanguination Protocol on Survival and Blood Product Utilization. Journal of Trauma, 2008, 64, 1177-1183.	2.3	342
94	Optimizing Outcomes in Damage Control Resuscitation: Identifying Blood Product Ratios Associated With Improved Survival. Journal of Trauma, 2008, 65, 527-534.	2.3	270
95	Vasopressors and inotropes. , 0, , 85-94.		0